Extension Study of Ataluren (PTC124) in Cystic Fibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

August 12, 2010

Primary Completion Date

December 2, 2013

Study Completion Date

December 2, 2013

Conditions
Cystic Fibrosis
Interventions
DRUG

Ataluren

Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.

Trial Locations (31)

10011

St. Vincent's Hospital, New York

10595

New York Medical College, Valhalla

15213

Childrens Hospital of Pittsburgh, Pittsburgh

21287

Johns Hopkins Children's Center, Baltimore

27599

University of North Carolina, Chapel Hill

30322

Emory University Cystic Fibrosis Center, Atlanta

31059

Hôpital des Enfants, Toulouse

33136

University of Miami, Miami

35233

University of Alabama-Birmingham, Birmingham

44106

Rainbow Babies & Children's Hospital, Cleveland

60614

Children's Memorial Hospital, Chicago

63110

Washington University, St Louis

80045

The Children's Hospital, Aurora

90806

Miller Children's Hospital Long Beach, Long Beach

91240

Hadassah University Hospital - Mount Scopus, Jerusalem

94304

Lucile Packard Children's Hospital, Palo Alto

02115

Children's Hospital Boston, Boston

Unknown

Hôpital Erasme, Brussels

Hôpital Universitaire des Enfants Reine Fabiola, Brussels

University Hospital Brussels, Brussels

University Hospital Leuven, Leuven

University of Toronto, Toronto

Hôpital Cochin, Paris

Hôpital Necker - Enfants Malades, Paris

Klinikum der Universität Köln, Cologne

Università La Sapienza, Roma

Azienda Ospedaliera di Verona, Verona

Universitair Medisch Centrum Utrecht, Utrecht

Hospital Universitario La Paz, Madrid

Karolinska University Hospital, Huddinge, Stockholm

Belfast City Hospital, Belfast

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

PTC Therapeutics

INDUSTRY

NCT01140451 - Extension Study of Ataluren (PTC124) in Cystic Fibrosis | Biotech Hunter | Biotech Hunter